Loading...

Welcome to Capten Therapeutics
NATURE
We pursue cancer immunotherapy with lessons from nature. Our approach mimics the immunogenic antigen presentation by a small molecule natural product that is further designed for selective processing and antigen presentation by the tumor cells.
OUR GOAL
Our goal is to create and develop drugs to treat patients with difficult to treat cancers.

HOME

Welcome to Capten Therapeutics

At Capten, we approach cancer immunotherapy by combining the knowledge gained from cancer vaccine development, specifically haptenated vaccines and immunogenic small molecule natural products. Our proprietary small molecules activate the immune system by enhancing the antigen presentation by cancer cells to T cells.

Our small molecule drugs are designed using a multipronged approach for achieving desired selectivity and they generate immune response in cells that are highly characteristic of tumor microenvironment, e.g., elevated ROS levels. They may be utilized as single agent drugs or in combination with appropriate existing anticancer drugs.

Read More

Our Team

    Weiwen Ying, Ph.D.
    Co-founder, President

    Weiwen Ying is an avid drug hunter with more than 15 years of research and development experience. While his tenure at Synta Pharmaceuticals, he created and championed the Hsp90 inhibitor program, that led to the clinical candidate ganetespib which completed the Ph3 trials. He was also the co-creator of the Hsp90 inhibitor drug conjugate (HDC) program.

    Dinesh Chimmanamada, Ph.D.
    Co-founder, Vice-President

    Dinesh Chimmanamada is an innovative concept and drug creator, specifically in oncology space. During his more than a decade long research at Synta pharmaceuticals, he has worked on multiple oncology programs. He co-created the Hsp90 Inhibitor Drug Conjugate (HDC) program, which led to the generation of a clinical candidate STA-8666.

"Capten’s approach does not presuppose the importance of any particular tumor-associated antigens, which I believe is a theoretical and practical advantage." - David Berd, MD, Cancer Vaccine Pioneer